skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Long-Term Outcomes of Stereotactic Radiosurgery for Treatment of Cavernous Sinus Meningiomas

Abstract

Purpose: Patients with cavernous sinus meningiomas (CSM) have an elevated risk of surgical morbidity and mortality. Recurrence is often observed after partial resection. Stereotactic radiosurgery (SRS), either alone or combined with surgery, represents an important advance in CSM management, but long-term results are lacking. Methods and Materials: A total of 88 CSM patients, treated from January 1991 to December 2005, were retrospectively reviewed. The mean follow-up was 86.8 months (range, 17.1-179.4 months). Among the patients, 22 were followed for more than 10 years. There was a female predominance (84.1%). The age varied from 16 to 90 years (mean, 51.6). In all, 47 patients (53.4%) received SRS alone, and 41 patients (46.6%) had undergone surgery before SRS. A dose of 14 Gy was prescribed to isodose curves from 50% to 90%. In 25 patients (28.4%), as a result of the proximity to organs at risk, the prescribed dose did not completely cover the target. Results: After SRS, 65 (73.8%) patients presented with tumor volume reduction; 14 (15.9%) remained stable, and 9 (10.2%) had tumor progression. The progression-free survival was 92.5% at 5 years, and 82.5% at 10 years. Age, sex, maximal diameter of the treated tumor, previous surgery, and complete targetmore » coverage did not show significant associations with prognosis. Among the 88 treated patients, 17 experienced morbidity that was related to SRS, and 6 of these patients spontaneously recovered. Conclusions: SRS is an effective and safe treatment for CSM, feasible either in the primary or the postsurgical setting. Incomplete coverage of the target did not worsen outcomes. More than 80% of the patients remained free of disease progression during long-term follow-up.« less

Authors:
 [1];  [1];  [1];  [1];  [1]
  1. Radiotherapy Department, Instituto Madrileno de Oncologia/Grupo IMO, Madrid (Spain)
Publication Date:
OSTI Identifier:
22054502
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 81; Journal Issue: 5; Other Information: Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; DISEASE INCIDENCE; FEMALES; HAZARDS; ISODOSE CURVES; MENINGES; MORTALITY; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIOTHERAPY; SEX; SINUSES; SURGERY

Citation Formats

Santos, Marcos Antonio dos, E-mail: marcosrxt@gmail.com, Bustos Perez de Salcedo, Jose, Gutierrez Diaz, Jose Angel, Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid, Calvo, Felipe A, Department of Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Samblas, Jose, Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid, Marsiglia, Hugo, Sallabanda, Kita, and Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid. Long-Term Outcomes of Stereotactic Radiosurgery for Treatment of Cavernous Sinus Meningiomas. United States: N. p., 2011. Web. doi:10.1016/J.IJROBP.2010.07.2002.
Santos, Marcos Antonio dos, E-mail: marcosrxt@gmail.com, Bustos Perez de Salcedo, Jose, Gutierrez Diaz, Jose Angel, Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid, Calvo, Felipe A, Department of Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Samblas, Jose, Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid, Marsiglia, Hugo, Sallabanda, Kita, & Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid. Long-Term Outcomes of Stereotactic Radiosurgery for Treatment of Cavernous Sinus Meningiomas. United States. https://doi.org/10.1016/J.IJROBP.2010.07.2002
Santos, Marcos Antonio dos, E-mail: marcosrxt@gmail.com, Bustos Perez de Salcedo, Jose, Gutierrez Diaz, Jose Angel, Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid, Calvo, Felipe A, Department of Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Samblas, Jose, Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid, Marsiglia, Hugo, Sallabanda, Kita, and Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid. 2011. "Long-Term Outcomes of Stereotactic Radiosurgery for Treatment of Cavernous Sinus Meningiomas". United States. https://doi.org/10.1016/J.IJROBP.2010.07.2002.
@article{osti_22054502,
title = {Long-Term Outcomes of Stereotactic Radiosurgery for Treatment of Cavernous Sinus Meningiomas},
author = {Santos, Marcos Antonio dos, E-mail: marcosrxt@gmail.com and Bustos Perez de Salcedo, Jose and Gutierrez Diaz, Jose Angel and Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid and Calvo, Felipe A and Department of Oncology, Hospital General Universitario Gregorio Maranon, Madrid and Samblas, Jose and Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid and Marsiglia, Hugo and Sallabanda, Kita and Neurosurgery Department, Sanatorio San Francisco de Asis, Madrid},
abstractNote = {Purpose: Patients with cavernous sinus meningiomas (CSM) have an elevated risk of surgical morbidity and mortality. Recurrence is often observed after partial resection. Stereotactic radiosurgery (SRS), either alone or combined with surgery, represents an important advance in CSM management, but long-term results are lacking. Methods and Materials: A total of 88 CSM patients, treated from January 1991 to December 2005, were retrospectively reviewed. The mean follow-up was 86.8 months (range, 17.1-179.4 months). Among the patients, 22 were followed for more than 10 years. There was a female predominance (84.1%). The age varied from 16 to 90 years (mean, 51.6). In all, 47 patients (53.4%) received SRS alone, and 41 patients (46.6%) had undergone surgery before SRS. A dose of 14 Gy was prescribed to isodose curves from 50% to 90%. In 25 patients (28.4%), as a result of the proximity to organs at risk, the prescribed dose did not completely cover the target. Results: After SRS, 65 (73.8%) patients presented with tumor volume reduction; 14 (15.9%) remained stable, and 9 (10.2%) had tumor progression. The progression-free survival was 92.5% at 5 years, and 82.5% at 10 years. Age, sex, maximal diameter of the treated tumor, previous surgery, and complete target coverage did not show significant associations with prognosis. Among the 88 treated patients, 17 experienced morbidity that was related to SRS, and 6 of these patients spontaneously recovered. Conclusions: SRS is an effective and safe treatment for CSM, feasible either in the primary or the postsurgical setting. Incomplete coverage of the target did not worsen outcomes. More than 80% of the patients remained free of disease progression during long-term follow-up.},
doi = {10.1016/J.IJROBP.2010.07.2002},
url = {https://www.osti.gov/biblio/22054502}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 81,
place = {United States},
year = {Thu Dec 01 00:00:00 EST 2011},
month = {Thu Dec 01 00:00:00 EST 2011}
}